GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » Price-to-Operating-Cash-Flow

BioCardia (BioCardia) Price-to-Operating-Cash-Flow : (As of Jun. 06, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BioCardia Price-to-Operating-Cash-Flow?

As of today (2024-06-06), BioCardia's share price is $4.40. BioCardia's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.14. Hence, BioCardia's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for BioCardia's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, BioCardia's highest Price-to-Operating-Cash-Flow Ratio was 903.79. The lowest was 4.04. And the median was 84.21.

BCDA's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.87
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

BioCardia's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.91. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.14.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 27.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 29.70% per year.

During the past 13 years, BioCardia's highest 3-Year average Operating Cash Flow per Share Growth Rate was 63.10% per year. The lowest was -35.50% per year. And the median was 32.00% per year.


BioCardia Price-to-Operating-Cash-Flow Historical Data

The historical data trend for BioCardia's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Price-to-Operating-Cash-Flow Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCardia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCardia's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, BioCardia's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioCardia's Price-to-Operating-Cash-Flow falls into.



BioCardia Price-to-Operating-Cash-Flow Calculation

BioCardia's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=4.40/-6.138
=

BioCardia's Share Price of today is $4.40.
BioCardia's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

BioCardia Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioCardia's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia (BioCardia) Business Description

Industry
Traded in Other Exchanges
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen officer: VP, Quality Assurance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous director C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070

BioCardia (BioCardia) Headlines

From GuruFocus

BioCardia Announces $3.6 Million Private Placement of Common Stock

By Value_Insider Value_Insider 12-15-2022